The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Associations between biomarker testing and characteristics of patients with metastatic non–small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.
 
Kathryn Finch Mileham
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Mirati Therapeutics; Regeneron
Speakers' Bureau - Merck
 
Elizabeth Garrett-Mayer
No Relationships to Disclose
 
Melinda Kaltenbaugh
No Relationships to Disclose
 
Margaret Kelsey Kirkwood
No Relationships to Disclose
 
Caroline Schenkel
No Relationships to Disclose
 
Suanna Steeby Bruinooge
No Relationships to Disclose
 
Raymond U. Osarogiagbon
Stock and Other Ownership Interests - Gilead Sciences; Lilly; Pfizer
Honoraria - Biodesix; Medscape
Consulting or Advisory Role - American Cancer Society; Association of Community Cancer Centers (ACCC); AstraZeneca; Biodesix; Genentech/Roche; Lilly; LUNGevity; National Cancer Institute; Triptych Health Partners
Patents, Royalties, Other Intellectual Property - 2 US and 1 China patents for lymph node specimen collection kit and method of pathologic evaluation.
Other Relationship - Oncobox
 
Shadia Ibrahim Jalal
Consulting or Advisory Role - Adaptimmune
Research Funding - Astex Pharmaceuticals; AstraZeneca/MedImmune; Tesaro
 
Amy Moore
Consulting or Advisory Role - Guardant Health; Merck (Inst)
 
Upal Kunal Basu Roy
Honoraria - AstraZeneca (Inst); AstraZeneca/MedImmune
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Takeda (Inst)
 
Janet Freeman-Daily
Consulting or Advisory Role - Genentech/Roche; Pfizer
Research Funding - Genentech (Inst); Turning Point Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - AnHeart Therapeutics (Inst); Genentech (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Turning Point Therapeutics (Inst)
 
Shamsuddin Virani
Employment - Walgreens (I)
Stock and Other Ownership Interests - BMY; Walgreens Boots Alliance
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Gerard A. Silvestri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Biodesix; Olympus Medical Systems
Research Funding - Amgen; biodesix; Olympus; Seer
 
Lauren Rosenthal
No Relationships to Disclose
 
Robert A. Smith
No Relationships to Disclose
 
Bruce E. Johnson
Consulting or Advisory Role - Boston Pharmaceuticals; Checkpoint Therapeutics; Daiichi Sankyo; Foundation Medicine; G1 Therapeutics; Genentech; GlaxoSmithKline; Hengrui Therapeutics; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Novartis
Research Funding - Novartis; Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute